Details of the Drug Combination

General Information of Drug Combination (ID: DCDL0DM)

Drug Combination Name
Nesvacumab Aflibercept
Indication
Disease Entry Status REF
Diabetic macular edema Phase 1 [1]
Component Drugs Nesvacumab   DM59ZDN Aflibercept   DMT3D5I
Antibody N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nesvacumab
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Nesvacumab Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Indication(s) of Aflibercept
Disease Entry ICD 11 Status REF
Central retinal vein occlusion with macular edema N.A. Approved [3]
Diabetic macular edema 9B71.02 Approved [4]
Exudative age-related macular degeneration 9B78.3Z Approved [5]
Metastasis from malignant tumor of colon N.A. Approved [6]
Metastatic colorectal cancer 2B91 Approved [7]
Aflibercept Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Modulator [7]
Vascular endothelial growth factor B (VEGFB) TTPJQHE VEGFB_HUMAN Modulator [7]
Placenta growth factor (PlGF) TT48I1Y PLGF_HUMAN Modulator [7]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01271972) Study of Nesvacumab (REGN910/ SAR307746). U.S. National Institutes of Health.
3 A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329.
4 Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci. 2022 Aug 20;23(16):9424.
5 Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020 Mar;37(3):1173-1187.
6 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clin Oncol (R Coll Radiol). 2022 Aug;34(8):e323-e328.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869.